Protalix BioTherapeutics opened lower at $3.12, compared with its previous close of $3.13. In the last trading session, the stock traded between $2.92 and $3.13. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Protalix BioTherapeutics is now worth
$ 268.64
Giving a profit of
$ 168.64 (168.64%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.18 (-5.59%)
Day High
$3.13
Day Low
$2.92
Day Open
$3.12
Prev Close
$3.13
Volume
23,28,771
1W Return
10.06%
1M Return
6.10%
3M Return
21.86%
6M Return
52.32%
1Y Return
38.73%
Fundamentals
Market Cap ($ Mn)
249
PE Ratio
11.04
PB Ratio
2.87
PEG Ratio
0.14
ROE
-13.79%
ROCE
-10.26%
EPS (TTM)
$0.05
Investment Returns
1 Week
10.06%
1 Month
6.10%
3 Months
21.86%
6 Months
52.32%
9 Months
1.20%
Financials
Quarterly
All values in $ Mn
15.7
Jun 25
17.9
Sep 25
9.1
Dec 25
33.8
Mar 26
19.9
Jun 26
21.9
Sep 26
Updates
10Nov
Protalix BioTherapeutics Q3FY26 Results: Revenue up 22% to $21.9M, net income rises 67%
Q3FY26 revenue rose 22% YoY to $21.9 million, driven by increased Elfabrio sales. Net income increased 67% YoY to $4.0 million, with EPS at $0.05. Full-year FY26 revenue guidance reaffirmed at $78.0 million to $83.0 million, above consensus. Cash position strengthened to $48.5 million with no outstanding debt or warrants. PRX-115 Phase 2 RELEASE study enrollment active, top-line results expected in H2 2027.
2 days ago
9Nov
Protalix PRX-115 data shows uric acid drop for 85 days
PRX-115 maintained measurable plasma levels for up to 85 days in Phase 1 participants. At 36 mg, mean plasma uric acid stayed below 6.0 mg/dL target for up to 12 weeks. Data supports potential for less frequent dosing in the ongoing Phase 2 RELEASE study. Top-line results from Phase 2 are expected in the second half of 2027.
Protalix BioTherapeutics delivered a mixed second-quarter report, characterized by a significant revenue beat and an earnings miss. Sales reached $19.896 million, surpassing estimates by 53.86 percent and growing 27.07 percent year-over-year. However, EPS of $0.05 fell short of the $0.12 consensus, missing by 58.33 percent.
